CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro
Copyright © 2021 Ma, Badeti, Chen, Kim, Choudhary, Honnen, Reichman, Calianese, Pinter, Jiang, Shi, Zhou, Xu, Li, Gause and Liu..
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is highly contagious and presents a significant public health issue. Current therapies used to treat coronavirus disease 2019 (COVID-19) include monoclonal antibody cocktail, convalescent plasma, antivirals, immunomodulators, and anticoagulants. The vaccines from Pfizer and Moderna have recently been authorized for emergency use, which are invaluable for the prevention of SARS-CoV-2 infection. However, their long-term side effects are not yet documented, and populations with immunocompromised conditions (e.g., organ-transplantation and immunodeficient patients) may not be able to mount an effective immune response. In addition, there are concerns that wide-scale immunity to SARS-CoV-2 may introduce immune pressure that could select for escape mutants to the existing vaccines and monoclonal antibody therapies. Emerging evidence has shown that chimeric antigen receptor (CAR)- natural killer (NK) immunotherapy has potent antitumor response in hematologic cancers with minimal adverse effects in recent studies, however, the potentials of CAR-NK cells in treating COVID-19 has not yet been fully exploited. Here, we improve upon a novel approach for the generation of CAR-NK cells for targeting SARS-CoV-2 and its various mutants. CAR-NK cells were generated using the scFv domain of S309 (henceforward, S309-CAR-NK), a SARS-CoV and SARS-CoV-2 neutralizing antibody (NAbs) that targets the highly conserved region of SARS-CoV-2 spike (S) glycoprotein and is therefore more likely to recognize different variants of SARS-CoV-2 isolates. S309-CAR-NK cells can specifically bind to pseudotyped SARS-CoV-2 virus and its D614G, N501Y, and E484K mutants. Furthermore, S309-CAR-NK cells can specifically kill target cells expressing SARS-CoV-2 S protein in vitro and show superior killing activity and cytokine production, compared to that of the recently reported CR3022-CAR-NK cells. Thus, these results pave the way for generating 'off-the-shelf' S309-CAR-NK cells for treatment in high-risk individuals as well as provide an alternative strategy for patients unresponsive to current vaccines.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 12(2021), Seite 652223 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ma, Minh Tuyet [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.08.2021 Date Revised 28.01.2022 published: Electronic-eCollection UpdateOf: bioRxiv. 2021 Jan 15;:. - PMID 33469580 Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2021.652223 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329112872 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329112872 | ||
| 003 | DE-627 | ||
| 005 | 20231226203416.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2021.652223 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM329112872 | ||
| 035 | |a (NLM)34367128 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ma, Minh Tuyet |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2021 | ||
| 500 | |a Date Revised 28.01.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a UpdateOf: bioRxiv. 2021 Jan 15;:. - PMID 33469580 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Ma, Badeti, Chen, Kim, Choudhary, Honnen, Reichman, Calianese, Pinter, Jiang, Shi, Zhou, Xu, Li, Gause and Liu. | ||
| 520 | |a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is highly contagious and presents a significant public health issue. Current therapies used to treat coronavirus disease 2019 (COVID-19) include monoclonal antibody cocktail, convalescent plasma, antivirals, immunomodulators, and anticoagulants. The vaccines from Pfizer and Moderna have recently been authorized for emergency use, which are invaluable for the prevention of SARS-CoV-2 infection. However, their long-term side effects are not yet documented, and populations with immunocompromised conditions (e.g., organ-transplantation and immunodeficient patients) may not be able to mount an effective immune response. In addition, there are concerns that wide-scale immunity to SARS-CoV-2 may introduce immune pressure that could select for escape mutants to the existing vaccines and monoclonal antibody therapies. Emerging evidence has shown that chimeric antigen receptor (CAR)- natural killer (NK) immunotherapy has potent antitumor response in hematologic cancers with minimal adverse effects in recent studies, however, the potentials of CAR-NK cells in treating COVID-19 has not yet been fully exploited. Here, we improve upon a novel approach for the generation of CAR-NK cells for targeting SARS-CoV-2 and its various mutants. CAR-NK cells were generated using the scFv domain of S309 (henceforward, S309-CAR-NK), a SARS-CoV and SARS-CoV-2 neutralizing antibody (NAbs) that targets the highly conserved region of SARS-CoV-2 spike (S) glycoprotein and is therefore more likely to recognize different variants of SARS-CoV-2 isolates. S309-CAR-NK cells can specifically bind to pseudotyped SARS-CoV-2 virus and its D614G, N501Y, and E484K mutants. Furthermore, S309-CAR-NK cells can specifically kill target cells expressing SARS-CoV-2 S protein in vitro and show superior killing activity and cytokine production, compared to that of the recently reported CR3022-CAR-NK cells. Thus, these results pave the way for generating 'off-the-shelf' S309-CAR-NK cells for treatment in high-risk individuals as well as provide an alternative strategy for patients unresponsive to current vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CAR (chimeric antigen receptor) | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a E484K variant | |
| 650 | 4 | |a N501Y variant | |
| 650 | 4 | |a NK cells | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a off-the-shelf | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Badeti, Saiaditya |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Chih-Hsiung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, James |e verfasserin |4 aut | |
| 700 | 1 | |a Choudhary, Alok |e verfasserin |4 aut | |
| 700 | 1 | |a Honnen, Bill |e verfasserin |4 aut | |
| 700 | 1 | |a Reichman, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Calianese, David |e verfasserin |4 aut | |
| 700 | 1 | |a Pinter, Abraham |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Qingkui |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Lanbo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Renping |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Huanbin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qingsheng |e verfasserin |4 aut | |
| 700 | 1 | |a Gause, William |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Dongfang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 12(2021), Seite 652223 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g pages:652223 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2021.652223 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |h 652223 | ||